Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma

Ingrid Spaan, Laura M Timmerman, Thomas Kimman, Anne Slomp, Marta Cuenca, Niels van Nieuwenhuijzen, Laura M Moesbergen, Monique C Minnema, Reinier A Raymakers, Victor Peperzak

Research output: Contribution to journalArticleAcademicpeer-review

8 Downloads (Pure)

Abstract

Novel combination therapies have markedly improved the lifespan of patients with multiple myeloma (MM), but drug resistance and disease relapse remain major clinical problems. Dexamethasone and other glucocorticoids are a cornerstone of conventional and new combination therapies for MM, although their use is accompanied by serious side effects. We aimed to uncover drug combinations that act in synergy and, as such, allow reduced dosing while remaining effective. Dexamethasone and the myeloid cell leukemia 1 (MCL-1) inhibitor S63845 (MCL-1i) proved the most potent combination in our lethality screen and induced apoptosis of human myeloma cell lines (HMCLs) that was 50% higher compared with an additive drug effect. Kinome analysis of dexamethasone-treated HMCLs revealed a reduction in serine/threonine peptide phosphorylation, which was predicted to result from reduced Akt activity. Biochemical techniques showed no dexamethasone-induced effects on FOXO protein or GSK3 but did show a 50% reduction in P70S6K phosphorylation, downstream of the Akt-mTORC1 axis. Replacing dexamethasone by the P70S6K1 isoform-specific inhibitor PF-4708671 (S6K1i) revealed similar and statistically significant synergistic apoptosis of HMCLs in combination with MCL-1i. Interestingly, apoptosis induced by the P70S6K1i and MCL-1i combination was more-than-additive in all 9 primary MM samples tested; this effect was observed for 6 of 9 samples with the dexamethasone and MCL-1i combination. Toxicity on stem and progenitor cell subsets remained minimal. Combined, our results show a strong rationale for combination treatments using the P70S6K inhibitor in MM. Direct and specific inhibition of P70S6K may also provide a solution for patients ineligible or insensitive to dexamethasone or other glucocorticoids.

Original languageEnglish
Pages (from-to)2593-2607
Number of pages15
JournalBlood Advances
Volume5
Issue number12
DOIs
Publication statusPublished - 22 Jun 2021

Keywords

  • Cell Line, Tumor
  • Dexamethasone/pharmacology
  • Glycogen Synthase Kinase 3
  • Humans
  • Multiple Myeloma/drug therapy
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Ribosomal Protein S6 Kinases, 70-kDa

Fingerprint

Dive into the research topics of 'Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma'. Together they form a unique fingerprint.

Cite this